After this date, only products which were on the market at the time of our announcement on CBD (13 February 2020) and for which the FSA has received an application which is subsequently validated will be allowed to remain on the market.
There are currently no authorised CBD extracts or isolates on the market.
If you buy CBD products from others, you must ensure these products are correctly authorised, and that you only use them in ways described in the authorisation.
Deadline for businesses to submit CBD applications to continue to sell existing products
CBD is one of many chemicals called cannabinoids. It is found within hemp and cannabis.
The authorisation itself is not specific to the applicant and the final product may be branded in different ways. However, if the applicant requests and is granted confidentiality, then key aspects of production and the research evidence base may not be available to others for five years.
Hemp and related products, such as cold-pressed oils, are not novel because there is evidence to show a history of consumption before May 1997. This is not the case for CBD extracts.
The deadline applies in England and Wales. Novel foods regulations in Scotland are covered by Food Standards Scotland.
CBD products are used to treat anxiety, inflammation, pain and a host of other medical conditions.
An analysis from Leafreport found that only 25% of CBD products are tested for purity.
Leafreport found that 25% of brands did not carry out any purity testing, noting that analyzing for contaminants is more expensive than potency testing. Only 13% of CBD brands carried out purity testing for at least 90% of their products to determine the presence of pesticide residue, heavy metals or microbial contamination. More than a third of brands (35%) published test results for only 10% or less of their offerings.
Why Millions Of Amateur Gamblers Will Bet On The Tokyo Olympics
A recent analysis of lab testing data has found that one out of four consumer CBD products is not tested for impurities including pesticides, heavy metals and microbial contamination. The investigation also discovered that the vast majority of CBD consumer goods are not labeled with accurate information detailing the potency of the products.
Dr. Stuart Titus, the former CEO of Medical Marijuana, Inc. and now a spokesperson for the family of hemp CBD brands, told Leafreport that all CBD products should be tested for contamination by an independent laboratory. Test results for the company’s brand HempMeds are available online.
In a report published last month, online CBD educational resource Leafreport reviewed the lab analysis data for 2,946 cannabidiol (CBD) products from 136 brands to determine how many companies test their products for purity and potency. The investigation also looked for discrepancies between the amount of CBD advertised on product packaging and the actual potency revealed by lab testing. With more and more consumers trying CBD to treat health conditions including anxiety, inflammation and pain, transparency in labeling can help them achieve the results they desire.
Titus said potency testing can help ensure that accurate information about the product’s cannabinoid concentrations is communicated to consumers.